ISCOMs: an adjuvant with multiple functions

Aluminum salts are currently the only widely used adjuvant for human vaccines. Over the past 10–15 years, a large research effort has attempted to find novel adjuvants with ability to induce abroad range of immune responses, including cell‐mediated immunity. The immunostimulating complex or ISCOM is one adjuvant with multiple adjuvant properties. ISCOMs are open cage‐like complexes typically with a diameter of about 40 nm that are built up by cholesterol, lipid, immunogen, and saponins from the bark of the tree Quillaia saponaria Molina. ISCOMs have been demonstrated to promote antibody responses and induce T helper cell as well as cytotoxic T lymphocyte responses in a variety of experimental animal models, and have now progressed to phase I and II human trials. This review describes recent developments in the understanding of the structure, composition, and preparation of ISCOMs and will cover important aspects of the understanding of the adjuvant functions of ISCOMs and how they act on the immune system. J. Leukoc. Biol. 64: 713–723; 1998.

[1]  J. Bates,et al.  Development of an Influenza-Iscom™ Vaccine , 1997 .

[2]  C. Kensil,et al.  Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. , 1992, Journal of immunology.

[3]  G. Wulff,et al.  Chemie und Biologie der Saponine , 1973 .

[4]  J. Brewer,et al.  Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. , 1996, Vaccine.

[5]  E. Tulman,et al.  Delivery of pseudorabies virus envelope antigens enclosed in immunostimulating complexes (ISCOMs); elicitation of neutralizing antibody and lymphoproliferative responses in swine and protection in mice. , 1994, Vaccine.

[6]  R. Rerko,et al.  Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. , 1995, Journal of immunology.

[7]  H. Braley‐Mullen,et al.  Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens. , 1986, Cellular immunology.

[8]  S. Kaufmann,et al.  Crossrecognition by CD8 T cell receptor alpha beta cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology. , 1995, European journal of immunology.

[9]  A. Osterhaus,et al.  Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene. , 1993, Vaccine.

[10]  R. Evans,et al.  The effect of saponin, sterols and linoleic acid on the weight increase of growing rats , 1960, British Journal of Nutrition.

[11]  L. S. Kind,et al.  Antigenic, Adjuvant and Permeability Enhancing Properties of Melittin in Mice , 1981, Allergy.

[12]  A. Sjölander,et al.  Iscoms in parasitological research. , 1996, Parasitology today.

[13]  M. Trudel,et al.  Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. , 1992, Vaccine.

[14]  S. Stacey,et al.  Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs). , 1996, Vaccine.

[15]  A. Osterhaus,et al.  Antigenicity and immunogenicity of recombinant envelope glycoproteins of SIVmac32H with different in vivo passage histories. , 1995, Vaccine.

[16]  G. Trinchieri,et al.  Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response. , 1997, Cytokine.

[17]  A. Osterhaus,et al.  The iscom structure as an immune-enhancing moiety: experience with viral systems. , 1992, Research in immunology.

[18]  R. Graziano,et al.  Cytotoxicity mediated by human Fc receptors for IgG. , 1989, Immunology today.

[19]  A. Osterhaus,et al.  A novel generation of viral vaccines based on the ISCOM matrix. , 1995, Pharmaceutical biotechnology.

[20]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.

[21]  T. Wrin,et al.  Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons . , 1994, AIDS research and human retroviruses.

[22]  A. Osterhaus,et al.  Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. , 1997, The Journal of infectious diseases.

[23]  J. Berzofsky,et al.  Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. , 1994, Journal of immunology.

[24]  L. Hilgers,et al.  Classical and new approaches to adjuvant use in domestic food animals. , 1990, Advances in veterinary science and comparative medicine.

[25]  R. Pipkorn,et al.  Antigenic presentation of small molecules and peptides conjugated to a preformed iscom as carrier. , 1987, Journal of immunological methods.

[26]  B. Morein,et al.  Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. , 1988, The Journal of general virology.

[27]  R. Baggs,et al.  Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. , 1995, Vaccine.

[28]  M. Villacrés-Eriksson,et al.  In vitro activation of antigen‐presenting cells (APC) by defined composition of Quillaja saponaria Molina triterpenoids , 1996, Clinical and experimental immunology.

[29]  A. Osterhaus,et al.  Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition , 1992, The Journal of experimental medicine.

[30]  M. Hansson,et al.  Immunogenicity in rabbits and monkeys of influenza ISCOMs conjugated with repeated sequences of the Plasmodium falciparum antigen Pf155/RESA , 1993, Parasite immunology.

[31]  K. Maloy,et al.  Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS , 1995, European journal of immunology.

[32]  G. Reid,et al.  Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid. , 1992, Vaccine.

[33]  J. Campbell,et al.  Immune responses of mice to inactivated rabies vaccine administered orally: potentiation by Quillaja saponin. , 1986, Canadian journal of microbiology.

[34]  J. Heeney,et al.  Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. , 1994, Vaccine.

[35]  R. F. Cook,et al.  Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. , 1994, Vaccine.

[36]  K. Heeg,et al.  Vaccination of class I major histocompatibility complex (MHC)‐restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: immunostimulating‐ovalbumin complexes enter the class I MHC‐restricted antigen pathway and allow sensitization against the immunodominant peptide , 1991, European journal of immunology.

[37]  C. Fossum,et al.  Antigen‐Specific Increases in the Number of Splenocytes Expressing MHC Class II Molecules Following Restimulation with Antigen in Various Physical Forms , 1992, Scandinavian journal of immunology.

[38]  M. Kazanji,et al.  Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeria falciformis in ISCOMs. , 1994, Vaccine.

[39]  K. Heeg,et al.  Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells. , 1994, Vaccine.

[40]  C. Fossum,et al.  Interactions between Immune‐Stimulating Complexes (ISCOMs) and Peritoneal Mononuclear Leucocytes , 1992, Microbiology and immunology.

[41]  D. O'hagan,et al.  Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. , 1994, Immunology.

[42]  B. Askonas,et al.  Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro , 1989, The Journal of experimental medicine.

[43]  E. Dotsika,et al.  ISCOMs vaccine against experimental leishmaniasis. , 1998, Vaccine.

[44]  A. Osterhaus,et al.  Canine distemper virus (CDV) immune-stimulating complexes (Iscoms), but not measles virus iscoms, protect dogs against CDV infection. , 1988, The Journal of general virology.

[45]  C. Fossum,et al.  Effect of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix. , 1990, Cellular immunology.

[46]  A. Sjölander,et al.  Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. , 1997, Cellular immunology.

[47]  J. F. Young,et al.  Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant. , 1992, Vaccine.

[48]  C. Kensil,et al.  Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. , 1994, Vaccine.

[49]  A. Sjölander,et al.  Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. , 1997, Vaccine.

[50]  B. Rönnberg,et al.  Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. , 1995, Vaccine.

[51]  E. C. Beuvery,et al.  On the structure of immune-stimulating saponin-lipid complexes (iscoms). , 1991, Biochimica et biophysica acta.

[52]  K. Simons,et al.  Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes. , 1985, Vaccine.

[53]  R. F. Cook,et al.  Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus of the homologous strain. , 1993, Research in veterinary science.

[54]  G. Nest,et al.  Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. , 1994, Journal of immunology.

[55]  M. Hansson,et al.  High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA. , 1991, Vaccine.

[56]  C. Hart,et al.  Stimulation of rotavirus IgA, IgG and neutralising antibodies in baboon milk by parenteral vaccination , 1995, Vaccine.

[57]  J. Hansen,et al.  Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[58]  K. Lövgren,et al.  Conjugation of synthetic peptides to carrier iscoms: factors affecting the immunogenicity of the conjugate. , 1994, Journal of immunological methods.

[59]  B. Vanselow,et al.  A bovine ephemeral fever vaccine incorporating adjuvant Quil A: a comparative study using adjuvants Quil A, aluminium hydroxide gel and dextran sulphate , 1985, Veterinary Record.

[60]  T. Fujioka,et al.  Structure of desacylsaponins obtained from the bark of Quillaja saponaria , 1986 .

[61]  D. Davis,et al.  Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes. , 1995, The Journal of infectious diseases.

[62]  B. McGwire,et al.  Iscom of viral envelope proteins protects against Aujeszky's disease. , 1989, Veterinary microbiology.

[63]  A. Sjölander,et al.  Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant. , 1996, Vaccine.

[64]  L. Arthur,et al.  Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120). , 1989, Vaccine.

[65]  M. Villacrés-Eriksson,et al.  Involvement of Interleukin‐2 and Interferon‐Gamma in the Immune Response Induced by Influenza Virus Iscoms , 1992, Scandinavian journal of immunology.

[66]  C. Kensil,et al.  Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant. , 1994, AIDS research and human retroviruses.

[67]  M. Pepys,et al.  Activation of mouse complement by different classes of mouse antibody. , 1979, Immunology.

[68]  D. Hockley,et al.  Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations. , 1989, The Journal of general virology.

[69]  A. Lundén,et al.  Immune responses in sheep after immunization with Toxoplasma gondii antigens incorporated into iscoms. , 1995, Veterinary parasitology.

[70]  M. Villacrés-Eriksson,et al.  In vivo and in vitro induction of IL-6 by Quillaja saponaria molina triterpenoid formulations. , 1997, Cytokine.

[71]  H. Grey,et al.  Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line , 1977, The Journal of experimental medicine.

[72]  I. Johnson,et al.  Brown Norway rat model of food allergy: effect of plant components on the development of oral sensitization. , 1996, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[73]  O. Jarrett,et al.  Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. , 1991, Immunology.

[74]  J. Berzofsky,et al.  Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. , 1993, Science.

[75]  A. Osterhaus,et al.  Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice. , 1988, The Journal of general virology.

[76]  M. Villacrés-Eriksson.  Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes , 1995, Clinical and experimental immunology.

[77]  A. Osterhaus,et al.  Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5) , 1995, Journal of virology.

[78]  K. Maloy,et al.  Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. , 1993, Immunology.

[79]  A. Delmas,et al.  Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization. , 1996, Vaccine.

[80]  C. Kensil,et al.  Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. , 1992, Journal of immunology.

[81]  A. Allison,et al.  An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. , 1986, Journal of immunological methods.

[82]  M. Ozel,et al.  Quaternary structure of the immunostimulating complex (iscom). , 1989, Journal of ultrastructure and molecular structure research.

[83]  W. Morrow,et al.  Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[84]  M. Trudel,et al.  Vaccination of rabbits with a bovine herpesvirus type 1 subunit vaccine: adjuvant effect of ISCOMs. , 1987, Vaccine.

[85]  B. Morein,et al.  Cellular Immune Responses in the Murine Lung to Local Immunization with Influenza A Virus Glycoproteins in Micelles and Immunostimulatory Complexes (Iscoms) , 1988, Scandinavian journal of immunology.

[86]  B. Morein.  Iscom--an immunostimulating complex. , 1987, Arzneimittel-Forschung.

[87]  L. Huang,et al.  Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. , 1993, Vaccine.

[88]  I. Barr,et al.  ISCOMs (immunostimulating complexes): The first decade , 1996, Immunology and cell biology.

[89]  I. Barr,et al.  ISCOMs and other saponin based adjuvants. , 1998, Advanced drug delivery reviews.

[90]  K. Nagaraja,et al.  A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection. , 1994, Vaccine.

[91]  B. Moss,et al.  Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. , 1994, The Journal of general virology.

[92]  T. Baldwin,et al.  Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. , 1998, Journal of immunology.

[93]  C. Kensil,et al.  Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. , 1991, Journal of immunology.

[94]  Y. S. Kwon,et al.  Effect of a novel saponin adjuvant derived from Quillaja saponaria on the immune response to recombinant hepatitis B surface antigen. , 1997, Molecules and cells.

[95]  Induction of CD8+ cytotoxic T-cells by immunization with purified HIV-1 envelope protein in ISCOMs. , 1991, Disease markers.

[96]  J. Berzofsky,et al.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs , 1990, Nature.

[97]  K. Lövgren,et al.  Immunopotentiation of synthetic oligopeptides by chemical conjugation to iscoms. , 1993, Journal of immunological methods.

[98]  D. Emery,et al.  Influence of antigens and adjuvants on the production of gamma‐interferon and antibody by ovine lymphocytes , 1990, Immunology and cell biology.

[99]  A. Osterhaus,et al.  Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine. , 1989, Vaccine.

[100]  T. Baldwin,et al.  Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. , 1998, Vaccine.

[101]  M. Villacrés-Eriksson,et al.  Influence of Quillaja saponaria Triterpenoid Content on the Immunomodulatory Capacity of Epstein–Barr Virus Iscoms , 1997, Scandinavian journal of immunology.

[102]  S. Alenius,et al.  Protective effect of an ISCOM bovine virus diarrhoea virus (BVDV) vaccine against an experimental BVDV infection in vaccinated and non-vaccinated pregnant ewes. , 1991, Vaccine.

[103]  H. Rammensee,et al.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine , 1989, Nature.

[104]  A. Osterhaus,et al.  ISCOMs and immunostimulation with viral antigens. , 1989, Sub-cellular biochemistry.

[105]  A. Mowat,et al.  Preservation of mucosal and systemic adjuvant properties of ISCOMS in the absence of functional interleukin‐4 or interferon‐γ , 1998, Immunology.

[106]  M. Browning,et al.  Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies. , 1992, Vaccine.

[107]  D. Taub,et al.  Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. , 1995, Journal of the National Cancer Institute.

[108]  C. Kensil,et al.  Structural and immunological characterization of the vaccine adjuvant QS-21. , 1995, Pharmaceutical biotechnology.

[109]  M. Tomasi.  13 – ISCOMs, Liposomes, and Oil-Based Vaccine Delivery Systems , 1996 .

[110]  A. Osterhaus,et al.  Antigen detection in vivo after immunization with different presentation forms of rabies virus antigen: involvement of marginal metallophilic macrophages in the uptake of immune‐stimulating complexes , 1995, European journal of immunology.

[111]  A. Osterhaus,et al.  Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. , 1997, The Journal of general virology.

[112]  D. Gerlier,et al.  Humoral immune response elicited in rats by measles viral membrane antigens presented in liposomes and ISCOMs. , 1988, Vaccine.

[113]  C. Kensil.  Saponins as vaccine adjuvants. , 1996, Critical reviews in therapeutic drug carrier systems.

[114]  R. Locksley,et al.  Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[115]  W. Britt,et al.  Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice. , 1995, The Journal of infectious diseases.

[116]  B. Morein,et al.  The requirement of lipids for the formation of immunostimulating complexes (iscoms) , 1988, Biotechnology and applied biochemistry.

[117]  K. Nagaraja,et al.  A lipid-conjugated immunostimulating complex subunit vaccine against Salmonella infection in turkeys. , 1993, Avian diseases.

[118]  P. Heegaard,et al.  Iscom immunization with synthetic peptides representing measles virus hemagglutinin. , 1992, Virus research.

[119]  S. Kaufmann,et al.  Crossrecognition by CD8 T cell receptor αβ cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology , 1995, European journal of immunology.

[120]  L. Stipkovits,et al.  Protective immunity induced in chicken by a single immunization with Mycoplasma gallisepticum immunostimulating complexes (ISCOMS). , 1996, Vaccine.

[121]  C. Kensil,et al.  Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection. , 1991, Journal of the American Veterinary Medical Association.

[122]  J. Löwer,et al.  Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. , 1995, Vaccine.

[123]  J. Cleland.  Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems. , 1995, Pharmaceutical biotechnology.

[124]  W. Gause,et al.  Early IL-4 production does not predict susceptibility to Leishmania major. , 1996, Experimental parasitology.

[125]  E. C. Beuvery,et al.  Incorporation of the major outer membrane protein of Neisseria gonorrhoeae in saponin-lipid complexes (iscoms): chemical analysis, some structural features, and comparison of their immunogenicity with three other antigen delivery systems , 1988, Infection and immunity.

[126]  F. Chiodi,et al.  Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. , 1994, Journal of acquired immune deficiency syndromes.

[127]  A. J. George.  LEGAL STATUS AND TOXICITY OF SAPONINS. , 1965, Food and cosmetics toxicology.

[128]  A. Sjölander,et al.  Kinetics, Localization and Isotype Profile of Antibody Responses to Immune Stimulating Complexes (Iscoms) Containing Human Influenza Virus Envelope Glycoproteins , 1996, Scandinavian journal of immunology.

[129]  K. Heeg,et al.  The immunodominant peptide from listeriolysin in Quil A liposomes vaccinates CD8+ cytolytic T cells and confers protection to infection. , 1994, Immunology letters.

[130]  M. Trudel,et al.  Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus. , 1989, Vaccine.

[131]  S. Höglund,et al.  Influenza virus ISCOMs: biochemical characterization. , 1988, Vaccine.

[132]  Defining protective responses to pathogens: cytokine profiles in leprosy lesions. , 1991, Science.

[133]  A. Osterhaus,et al.  Canine distemper virus ISCOMs induce protection in harbour seals (Phoca vitulina) against phocid distemper but still allow subsequent infection with phocid distemper virus-1. , 1992, Vaccine.